Erenumab (Aimovig®) is indicated for the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab.
| NCPE Assessment Process | Complete |
| Rapid review received | 19/07/2018 |
| Rapid review completed | 15/08/2018 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/08/2018 |
| Pre-submission consultation with Applicant | 24/09/2018 |
| Submission received from Applicant | 22/01/2019 |
| Preliminary review sent to Applicant | 01/04/2019 |
| NCPE assessment re-commenced | 01/05/2019 |
| Factual accuracy sent to Applicant | 31/07/2019 |
| NCPE assessment re-commenced | 06/08/2019 |
| NCPE assessment completed | 30/09/2019 |
| NCPE assessment outcome | Chronic Migraine: The NCPE recommends that erenumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*
Episodic Migraine: The NCPE recommends that erenumab not be considered for reimbursement.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.